AbbVie continues to demonstrate solid revenue and earnings growth driven by the strong performance of Skyrizi and Rinvoq, which compensate for declines in Humira sales. Recent regulatory approvals and expanded market opportunities support the company's long-term growth prospects. Although AbbVie's forward price-to-earnings ratio has risen to 18.89, it still trades at a discount compared to its sector peers, with a forward PEG ratio of 1.40 indicating undervaluation. The analyst maintains a buy rating based on AbbVie's robust fundamentals and growth drivers, despite risks related to its drug pipeline and policy environment.
The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, impr...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
AbbVie announced positive Phase 3 INTREPID study results for lutikizumab, a dual IL-1α/1β antagonist, in treating moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint with 31.4% of patients achieving HiSCR75 at Week 16...
Retirees are increasingly turning to high-yield dividend stocks from diverse industries to supplement income beyond Social Security's fixed cost-of-living adjustments. Stocks like Verizon, Altria, AbbVie, Realty Income, and Enbridge offer yields from...
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
